As Amyloid Falls Out of Favor, Here’s Where Alzheimer’s R&D Is Headed Next

Why It Matters

The diversification away from amyloid signals a potential breakthrough in addressing unmet therapeutic needs, reshaping investment and R&D priorities across the biotech sector.

Key Takeaways

• Amyloid‑targeting drugs now only 16% of pipeline
• Disease‑modifying strategies comprise 73% of investigational agents
• Inflammation, immune and tau approaches together exceed 30% of trials
• Repurposed drugs like metformin account for over one‑third of candidates
• Biomarkers guide patient enrollment in >50% of Alzheimer trials

Pulse Analysis

The Alzheimer’s research landscape is undergoing a fundamental shift. After a decade of disappointment with amyloid‑centric therapies, the 2026 pipeline shows unprecedented breadth, encompassing 158 novel agents and 192 active trials. This diversification reflects a strategic pivot toward disease‑modifying mechanisms, with 73% of candidates targeting underlying pathology rather than merely alleviating symptoms. The decline of amyloid‑focused drugs to 16% underscores industry fatigue, while new delivery platforms, such as Roche’s brain‑shuttle, aim to revive interest in the pathway by overcoming the blood‑brain barrier.

Emerging therapeutic classes now dominate the pipeline. Inflammation and immune modulation account for 18% of candidates, capitalizing on evidence that neuroinflammation may precede cognitive decline. Tau‑targeting antibodies, exemplified by Merck’s MK‑2214 and Biogen’s BIIB080, represent 9% of the portfolio, offering a parallel route to disrupt neurofibrillary tangles. Neurotransmitter‑focused agents make up 24%, many of which are repurposed drugs like the schizophrenia therapy Cobenfy. This repurposing trend, covering over a third of the pipeline, accelerates development timelines and leverages existing safety data, attracting both biotech firms and large pharma.

Biomarkers have become the linchpin of modern Alzheimer’s trials. More than half of ongoing studies now employ biomarkers for patient selection, and 27% use them as primary endpoints, improving trial efficiency and predictive power. The integration of fluid and imaging markers enables precise enrollment of individuals most likely to respond, reducing costly failures. As several Phase 3 studies, including AriBio’s AR1001, conclude this year, the industry anticipates data that could validate these new mechanisms and reshape market dynamics, offering hope to a growing patient population facing limited treatment options.